Bate Kenneth
- SEC CIK
- 0001210238
In the past year, 1 open-market sale filing worth $8.03M and no purchases.
Current role at each company
- ATXS Astria Therapeutics, Inc.Directoras of Jan 23, 2026
- MDGL Madrigal Pharmaceuticals, Inc.Directoras of Nov 7, 2025
- AVEO Aveo Pharmaceuticals, Inc.Directoras of Jan 19, 2023
- EPZM Epizyme, Inc.Directoras of Aug 16, 2022
- GNCA Genocea Biosciences, Inc.Directoras of Jul 2, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $8.03M
- 1 filing
- Net
- −$8.03M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Bate Kenneth as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
MDGL Madrigal Pharmaceuticals, Inc.
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 3, 2024 (view filing) | Apr 1-2 | 2 days | Bate KennethDirector | SSale | −32.5K | $252.86 | −$8.22M | −96.4%1.20K after | 17 lots10b5-1 |
| Feb 28, 2025 (view filing) | Feb 27 | 1 day | Bate KennethDirector | SSale | −20.0K | $356.44 | −$7.13M | −91.3%1.91K after | 9 lots |
| Aug 15, 2025 (view filing) | Aug 15 | Same day | Bate KennethDirector | SSale | −10.0K | $365.20 | −$3.65M | −79.2%2.63K after | 6 lots |
| Nov 7, 2025 (view filing) | Nov 5 | 2 days | Bate KennethDirector | SSale | −16.6K | $484.31 | −$8.03M | −86.3%2.63K after | 11 lots |